Skip to main content
. 2017 Jan 23;2017(1):CD004753. doi: 10.1002/14651858.CD004753.pub4

Summary of findings for the main comparison. NSAID compared with placebo for pain in women with endometriosis.

NSAID compared with placebo for pain in women with endometriosis
Patient or population: women with endometriosis
 Setting: Finland
 Intervention: nonsteroidal anti‐inflammatory drugs (NSAIDs)
 Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
 (95% CI) Number of participants
 (studies) Quality of the evidence
 (GRADE) Comments
Risk with placebo Risk with NSAID
Pain relief assessed with: overall pain relief score follow‐up: median 2 months 50 per 100 77 per 100
 (38 to 95) OR 3.27
 (0.61 to 17.69) 24
 (1 RCT) ⊕⊝⊝⊝
 Very lowa,b  
Unintended effects from treatment follow‐up: median 2 months 58 per 100 39 per 100
 (11 to 78) OR 0.46
 (0.09 to 2.47) 24
 (1 RCT) ⊕⊝⊝⊝
 Very lowa,b  
Quality of life: not reported  
Effects on daily activities: not reported  
Absence from work or school: not reported  
Number of women requiring more invasive treatment: not reported  
Requirements for additional medication follow‐up: median 2 months 83 per 100 38 per 100
 (5 to 87) OR 0.12
 (0.01 to 1.29) 24
 (1 RCT) ⊕⊝⊝⊝
 Very lowa,b  
Participant satisfaction with treatment: not reported            
*The risk in the intervention group (and its 95% confidence interval) is based on assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
 
 CI: confidence interval; OR: odds ratio.
GRADE Working Group grades of evidence.High quality: We are very confident that the true effect lies close to the estimate of effect.
 Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.
 Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.
 Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level owing to overall unclear risk of bias for included trial.

bDowngraded two levels for imprecision because confidence interval is wide, consistent with benefit and harm and evidence based on a single small trial.